REGISTER
Sara A. Hurvitz on TALENT and T-DXd in HER2-Low Early Breast Cancer
At ESMO 2026, Sara A. Hurvitz reviews TALENT, a phase 2 study of neoadjuvant T-DXd in hormone receptor-positive, HER2-low early breast cancer. She discusses pathological complete response, safety, and the biomarker evidence still needed to identify candidates for chemotherapy de-escalation.

0
0
Loading